Investigational Parkinson’s disease dementia therapy fails in clinical trial

News

Author: Sophie ParrottPublished: 16 March 2023

Prep: Cook: Serves:

Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase.

This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study.

The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function.

Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did not validate the therapeutic potential observed previously in preclinical studies of NYX-458 in models of cognitive impairment.”

Find out more about Aptinyx’s Phase 2 clinical trial.

To find out more about the latest Parkinson’s research, please visit the Parkinson’s Europe website.

A new “promising approach” to Parkinson’s disease treatment?

Last Month

Next Month

Go Back

Share this story

Comments

Global update

How does the impact of DBS vary across Parkinson’s disease subtypes?

Exploring the treatment’s effect on non-motor symptoms

A new “promising approach” to Parkinson’s disease treatment?

Read about an upcoming research trial from Sweden and the UK

Call for increased research into drug targets for neurodegenerative conditions

What could this achieve for people with Parkinson’s disease?

Could certain cancers be linked to Parkinson’s disease?

Previous research has suggested that people with Parkinson’s may generally be less likely to develop most cancers. However, a new international study has found a potential genetic link between certain types of cancer and the condition. The team analysed genetic data from genome-wide association studies – a research approach that aims to identify gene variations associated with disease risk – to recognise common genetic risk factors between cancer and Parkinson’s. The findings uncovered a genetic link between the condition and both prostate cancer and melanoma. Meanwhile, the sum of various gene variants (otherwise known as the polygenic risk score) that contribute to Parkinson’s was significantly associated with a higher risk of breast cancer. “Our results suggest the importance of shared genetic variants between Parkinson’s and some cancers,” the researchers concluded in the study, which was published in the medical journal ‘Movement Disorders’. They highlighted the need for further studies to…

Investigational Parkinson’s disease dementia therapy fails in clinical trial

Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…

A new intimacy guide aims to support people with Parkinson’s disease in the US

Does sexual wellness in the Parkinson’s community need more focus? It’s an area that the American Parkinson Disease Association (APDA) and media brand Havas Health Plus have targeted through the launch of a free intimacy guide. Available to people in the US, ‘The ParkinSex Booklet & Kit’ aims to support those whose relationships may have been impacted by emotional and physical distance linked to the condition. Alongside an educational guide, the kit includes items such as candles, coupons for adaptative clothing and massage stones. Following a positive response to an initial pilot distribution of the guides in the US, there is now a waitlist for future kits. Commenting on the launch in a press release, APDA president and CEO Leslie Chambers said: “The challenges of Parkinson’s can often result in intimacy and connection getting left behind. This is why we created ‘The ParkinSex Booklet & Kit’, to help people with…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

Investigational Parkinson’s disease dementia therapy fails in clinical trial

News

Author: Sophie ParrottPublished: 16 March 2023

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

How does the impact of DBS vary across Parkinson’s disease subtypes?

Advances

A new “promising approach” to Parkinson’s disease treatment?

Global update

Call for increased research into drug targets for neurodegenerative conditions

Could certain cancers be linked to Parkinson’s disease?